Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary highlights strong financial metrics such as an increase in EPS guidance and operating margins, a major acquisition with significant synergies, and an expansive innovation pipeline. The Q&A section supports this positive outlook, with management addressing growth strategies and synergies effectively. However, the unchanged EPS CAGR guide and higher leverage are slight concerns. Overall, the strategic initiatives and optimistic guidance suggest a positive stock price movement, likely in the 2% to 8% range.
Revenue from continuing operations $3.6 billion, a record high, with a year-over-year adjusted diluted EPS growth of 17%. The increase includes the contribution of Hanes since December 1, 2025, and reflects strong competitive positioning and market share gains.
Q4 Sales from continuing operations $1.078 billion, up 31.3% year-over-year. Organic growth was 4.9% excluding Hanes' contribution of $217 million. Growth was driven by favorable mix, higher net selling prices, and strong demand in North America.
Activewear Sales $788 million, up 10.3% year-over-year. Growth was driven by the Hanes acquisition, favorable mix, higher net selling prices, and strong demand from North American distributors and national account customers.
Innerwear Sales Up 171% year-over-year, primarily due to HanesBrands' contribution in December, offset by slightly lower volumes due to broader market weakness.
International Market Sales $68 million, up 5.1% year-over-year, driven by the Hanes acquisition but partially offset by demand softness in markets like the U.K.
Gross Profit for Q4 $312 million or 28.9% of net sales, compared to $253 million or 30.8% in the prior year. Adjusted gross profit was $347 million or 32.2% of net sales, reflecting favorable pricing, lower manufacturing and raw material costs, and HanesBrands' contribution.
SG&A Expenses for Q4 $125 million, up from $78 million in the prior year, primarily due to the HanesBrands acquisition and purchase accounting impacts.
Adjusted Operating Income for Q4 $223 million, up $48 million year-over-year, reflecting HanesBrands' lower adjusted operating margin.
Adjusted Operating Margin for Full Year 2025 21.5% of net sales, up 20 basis points year-over-year, driven by favorable pricing and cost efficiencies.
Net Financial Expenses for Q4 $43 million, up $16 million year-over-year, due to higher borrowing levels related to the HanesBrands acquisition.
Adjusted Diluted EPS for Q4 $0.96, up 16% year-over-year, reflecting the HanesBrands acquisition and operational efficiencies.
Adjusted Diluted EPS for Full Year 2025 $3.51, up 17% year-over-year, driven by the HanesBrands acquisition and strong operational performance.
Operating Cash Flow for 2025 $606 million, up from $501 million in the prior year, reflecting lower working capital investment.
Free Cash Flow for 2025 $493 million, after accounting for $114 million in capital expenditures, reflecting strong cash generation.
Net Debt at Year-End 2025 $4.417 billion, with a leverage ratio of 3x net debt to trailing 12 months pro forma adjusted EBITDA.
New product launches: Introduction of new soft cotton technology and new brands such as Champion and ALLPRO.
Market expansion: Sales to North American distributors showed solid growth, and there was continued growth with national account customers. Expansion in Bangladesh with Phase 2 of the Bangladesh complex, including a second large-scale textile facility to support growth plans for 2028.
Operational efficiencies: Integration of HanesBrands progressing ahead of plan, including manufacturing footprint optimization and closure of two Hanes textile factories in early 2026. Optimization of distribution capacity, standardization of IT platforms, and harmonization of supply chain processes. Anticipated $250 million in run-rate cost synergies over the next 3 years, up from the original $200 million target.
Strategic shifts: Acquisition of HanesBrands, doubling scale and combining iconic brands with Gildan's platform. Decision to sell HanesBrands Australia business (HAA) to focus on core operations. Reorganization of internal sales teams to align with go-to-market strategy, transitioning to retail and wholesale-based reporting.
Manufacturing Footprint Optimization: The decision to close two Hanes textile factories in early 2026 and relocate production volumes across the consolidated network may lead to short-term capacity constraints and disruptions in inventory levels.
Inventory Reduction: Proactively reducing inventory levels across customer channels could temporarily impact sales and operational efficiency.
Integration of HanesBrands: The integration process, including standardizing IT platforms and harmonizing supply chain processes, poses risks of delays or inefficiencies that could affect operations.
HanesBrands Australia Business Sale: The sale of the HanesBrands Australia business introduces uncertainty regarding the valuation and terms of the transaction, which could impact financial outcomes.
Tariff Environment: The dynamic and uncertain tariff environment, including potential changes and mitigation initiatives, could affect costs and pricing strategies.
Debt Levels: High borrowing levels related to the HanesBrands acquisition have increased financial expenses and leverage, posing risks to financial stability.
Market Demand Softness: Demand softness in international markets, particularly in the U.K., could impact revenue growth.
Temporary Inventory Costs: Higher tariff costs embedded in inventory costs prior to recent developments could affect profitability.
Restructuring Costs: The restructuring costs associated with achieving synergies may strain financial resources if not managed effectively.
Revenue Expectations: For 2026, Gildan expects revenue of $6 billion to $6.2 billion from continuing operations, excluding the contribution from HanesBrands Australia (HAA).
Adjusted Operating Margin: The full-year adjusted operating margin is projected to be approximately 20% for 2026.
Adjusted Diluted EPS: Adjusted diluted EPS is expected to range between $4.20 and $4.40 for 2026.
Free Cash Flow: Free cash flow is projected to exceed $850 million in 2026.
Capital Expenditures: CapEx is expected to be approximately 3% of net sales in 2026.
Synergy Expectations: The company has raised its synergy expectations to approximately $250 million in run-rate cost synergies over the next 3 years, with $100 million expected annually in 2026 and 2027, and at least $50 million in 2028.
Bangladesh Expansion: Phase 2 of the Bangladesh complex will begin construction over the next 18 months, with initial production expected in late 2027 to support growth plans for 2028.
3-Year Objectives (2026-2028): The company aims for compound annual net sales growth of 3% to 5% and adjusted diluted EPS growth in the low 20% range compared to fiscal 2025.
First Quarter 2026 Guidance: Net sales from continuing operations are expected to be approximately $1.15 billion, with an adjusted operating margin of approximately 12.9%.
Dividends Paid: During 2025, the company returned $319 million to shareholders, which included dividends paid.
Share Repurchase Program: The company repurchased about 3.8 million shares under its NCIB program in 2025. However, it was stated that there will be no share repurchases until the net debt leverage ratio approximates the midpoint of the target leverage framework of 1.5 to 2.5x net debt to trailing 12 months pro forma adjusted EBITDA.
The earnings call summary indicates mixed results. Basic financial performance shows positive cash flow and asset sales progress, but EBITDA decline in the tissue segment is concerning. Product development is promising with innovation plans, but market strategy is unclear due to potential tariff impacts. The shareholder return plan lacks detail on capital allocation priorities. Q&A insights reveal confidence in price hikes and asset sales without EBITDA erosion, but management's unclear responses on tariffs and asset mix raise uncertainties. Overall, the sentiment is neutral, balancing positive and negative factors.
The earnings call summary highlights strong financial metrics such as an increase in EPS guidance and operating margins, a major acquisition with significant synergies, and an expansive innovation pipeline. The Q&A section supports this positive outlook, with management addressing growth strategies and synergies effectively. However, the unchanged EPS CAGR guide and higher leverage are slight concerns. Overall, the strategic initiatives and optimistic guidance suggest a positive stock price movement, likely in the 2% to 8% range.
The earnings call summary and Q&A reveal a stable market with expected growth in key areas, such as Activewear and Comfort Colors. Despite some concerns in the innerwear business and imprintables market, management expects improvement. Strong financial metrics, including margin improvements and shareholder returns, coupled with optimistic guidance, suggest a positive outlook. The company's strategic positioning amidst tariff challenges also adds to the positive sentiment. Thus, a stock price increase of 2% to 8% is anticipated over the next two weeks.
The earnings call summary and Q&A reflect a positive sentiment. Strong financial performance in Q2, optimistic guidance, and strategic initiatives like new product launches and capacity expansion in Bangladesh support this. Although there were some vague responses, overall, the company is well-positioned for growth, with improved operating margins, shareholder returns, and market share gains. The positive outlook for revenue and EPS, despite some risks, suggests a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.